. (1974). Archives of Disease in Childhood, 49, 297. Primary somatomedin deficiency: case report. A child presenting with the clinical features of hyposomatotropism but with high immunoreactive plasma growth hormone is described. During short-term administration of human growth hormone (HGH) his response with regard to fasting blood-glucose and free fatty acids, plasma-somatomedin, urinary excretion of calcium, nitrogen, and hydroxyproline was minimal or absent. 6 months of treatment with HGH did not reduce the endogenous HGH secretion. Insulin secretion had not increased and plasma somatomedin levels remained extremely low. Over a period of 2 years of treatment, growth response and loss of subcutaneous fat were minimal. On serial dilution in radioimmunoassay, his growth hormone (GH) molecule yielded a parallel line with the HGH standard. In electrofocusing experiments the GH molecule was in the same pH range as growth hormone in acromegalic plasma and the major peak of clinical grade HGH (5 03 against 5 * 01 and 4 * 98).
. During the first days of life he was noted to drink poorly and to vomit occasionally. Psychomotor development was normal. Growth was slow from early in life ( Fig. 1) . At the age of 2 years he had documented hypoglycaemic spells for which he was given cortisone (5 mg/day). An attempt to increase his growth rate with ethyloestrenol (Orgabolin, Organon) 0 5 mg/day during 6 months failed. Cortisone was discontinued at the age of 6 years when Perthes-like deformities were discovered in both hips. All treatment was withheld until he was aged 10 years 2 months when he was admitted for the present studies. Family history was negative for short stature. Father's height 170-7 cm (>10th centile), mother's height 155-7 cm (about 3rd centile) (Van Wieringen, 1972 Van Wieringen, 1972) . Growth hormone administration caused only a slight increase in growth rate in Case 1. The control patient, Case 2, with isolated GH deficiency responded to GH treatment with a pronounced growth spurt.
tension after the 36th week. Birthweight 3500 g (equal to the mean for gestational age), length 50 cm (-1 * 5 SD) (Usher and McLean, 1969) . During the first days of life he drank poorly and vomited occasionally. He was noticed to grow slowly (Fig. 1 ). His psychomotor development was quite normal. He had had no history of hypoglycaemia and had received no medication before admission to hospital. Family history was negative for short stature. The parents were full cousins.
Materials and methods Growth hormone and insulin were measured with a charcoal dextran radioimmunoassay . Urinary total nitrogen, calcium, phosphorus, creatinine, and 17-hydroxysteroids, as well as blood glucose and free fatty acids were measured using routine methods (Fawcett and Scott, 1960; Dunsbach, 1963; Fiske and Subbarow, 1925 ; De Vries and Van Daatselaar as described by Gorter and De Graaf, 1955; Degenhart, 1974; Schmidt, 1963; Ko and Royer, 1967; Korovina, Vel'tishchev, and Lempert, 1966) . Total urinary hydroxyproline was determined with the Hypronosticon test (Organon) (Goverde and Veenkamp, 1972) . Plasma somatomedin was measured with a double isotope technique, using hypophysectomized rat or normal monkey rib cartilage (Van den Brande et al., 1971b) .
For the electrofocusing experiments, an LKB 8102 Ampholyne column (440 ml) was used with LKB ampholite ranging from pH 3 to 6. The procedure was as described earlier . Equilibration time was between 60 and 120 hours. Fractions were tested for their growth hormone content by radioimmunoassay.
Results
Physical examination. The physical appearance of both boys was very similar (Fig. 2) . The abnormalities were more pronounced in Case 1 than in Case 2. Both were short, obese, and reasonably well proportioned. Some details are given in Table I Plasma insulin levels were also measured during the arginine infusion test and were low in both cases. Though their peak values were similar (Case 1 8, Case 2 9 [XU/ml), Case 1 had a sustained baseline level between 4 and 6 tU/ml, whereas the baseline was less than 1 ,uU/ml in Case 2.
Plasma somatomedin measured in the hypophysectomized rat assay was equally low for both patients as compared to two acromegalics. This low value was found both when 35S-sulphate and when the 3H-thymidine incorporation was used as an index of somatomedin activity (Fig. 4) .
Short-term metabolic studies (Table II Urinary nitrogen/creatinine ratio fell slightly in Case 1 and drastically in Case 2. The fall was significant for both patients, but the differences between them were large.
Urinary hydroxyproline/creatinine ratio decreased somewhat in Case 1 and doubled in Case 2.
Plasma somatomedin was measured in pretreatment plasma and on the fourth day of GH treatment. In baseline conditions both patients were indistinguishable. On treatment the somatomedin activity of Case 2 rose to approximately three times the baseline levels, whereas Case 1 remained unchanged, both when the results were expressed as 35S-sulphate and as 3H-thymidine incorporation.
Effect of long-term GH treatment. Linear growth and skinfold thickness. Over periods of 2 years before and on treatment, Case l's growth rate increased from 3A1 cm/year to 4-6 cm/year as compared to an increase from 3 * 3 to 9 * 2 cm/year in the control patient, Case 2. Over the same period of treatment, average skinfold thickness, measured with a Harpenden caliper at 8 sites, after an initial decrease to 90 5% of the initial value, increased again to 99 6% in Case 1, while it decreased to 58 4% in Case 2 (Table I) .
Skeletal maturation advanced 2-3 years in Case 1 and 2 -5 years in Case 2 over the same 2-year period (Tanner et al., 1962 Some immunological and physicochemical characteristics of endogenous growth hormone in Case 1. In order to study possible differences in immunological characteristics, plasma was serially diluted, growth hormone was estimated by radioimmunoassay, and the slopes obtained were compared. No significant deviation from parallelism could be shown (Fig. 7) .
In order to find possible differences in charge, plasma from Case 1 was electrofocused and compared both with plasma from an acromegalic and with HGH (same preparation as used for treatment). GH was localized by radioimmunoassay.
Initially, GH in Case l's plasma focused at a wide peak with a suggestion of two maxima (Van den Brande et al., 1971a) . After improving the technique by selecting the more appropriate pH range of 3 to 6 instead of 5 to 8, and using the same Laron et al. (1968) seemed to respond to exogenous HGH with nitrogen retention, lipolysis, and increased growth rate. More recently, however, after a longer period of observation, the authors concluded that the metabolic and growth responses of their patients were variable but mostly lacking (Merimee et al., 1968; Tanner et al., 1971; Najjar et al., 1971; Elders et al., 1971; New et al., 1972) . Laron et al. (1971) favour the hypothesis that the GH molecule in such patients might have an abnormal structure, lacking biological activity but with the preservation of its immunological characteristics. The subnormal response to exogenous HGH could be the consequence of an unsuccessful competition with the endogenous molecule for binding sites. Daughaday et al. (1969) found low plasma somatomedin levels both before and while on treatment with HGH in Laron's patients. They suggested that defective somatomedin generation may be responsible for the growth failure, while the other abnormalities such as lack of lipolysis, nitrogen retention, and calciuria may be the expression of a more generalized defect in growth hormone response. New et al. (1972) came to similar conclusions. Our patient, Case 1, also presents with a complete picture of hyposomatotropism, including not only short stature and the typical appearance, but also hypoglycaemia, A group.bmj.com on June 21, 2017 -Published by http://adc.bmj.com/ Downloaded from insulinopenia, and low plasma somatomedin levels. Noteworthy is the short length at birth with slightly increased weight. Laron et al. (1968) also found short birth length in half of their patients. Some GH dependency of intrauterine growth at the end of pregnancy is thus suggested.
The endogenous growth hormone, present at very high levels in plasma, cannot be distinguished from normal growth hormone, either from its immunological behaviour, or from its isoelectric point.
Our results with short-term, high dosage treatment with HGH confirm previous reports: metabolic indices of growth hormone effect such as blood glucose, nitrogen retention, calciuria, and hydroxyproline excretion are little if at all altered. Somatomedin is low both before and while on treatment. The finding of others Tanner et al., 1971; Najjar et al., 1971; New et al., 1972) (1971) reported that in acute conditions the endogenous GH secretion could not be suppressed by exogenous administration of the hormone, we found that prolonged treatment also was not effective in this regard. Insulinopenia and low plasma somatomedin levels, which had been shown by others to be resistant to acute GH treatment Elders et al., 1971; New et al., 1972) were still unchanged after 6 months of administration of the hormone.
All these findings suggest a specific and overall impaired responsiveness to growth hormone. The alternative hypothesis of an abnormal endogenous GH molecule lacks support at present.
While in patients such as ours all effects of GH are diminished, its failure to induce somatomedin seems to be the most crucial. Since somatomedin is supposed to mediate the growth-promoting effect of GH 
